{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:17:33Z","timestamp":1788221853787,"version":"build-2803163510"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:00:00Z","timestamp":1780099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":94,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000774","name":"Defense Threat Reduction Agency","doi-asserted-by":"publisher","award":["HDTRA1035955001"],"award-info":[{"award-number":["HDTRA1035955001"]}],"id":[{"id":"10.13039\/100000774","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000774","name":"Defense Threat Reduction Agency","doi-asserted-by":"publisher","award":["HDTRA1035955001"],"award-info":[{"award-number":["HDTRA1035955001"]}],"id":[{"id":"10.13039\/100000774","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["2U54GM104942"],"award-info":[{"award-number":["2U54GM104942"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Antimicrob Resist"],"DOI":"10.1038\/s44259-026-00225-4","type":"journal-article","created":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T07:44:51Z","timestamp":1780127091000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Machine learning-based discovery of GW3965 as a therapeutic compound against invasive emm92-type group A Streptococcus"],"prefix":"10.1038","volume":"4","author":[{"given":"Lillie M.","family":"Powell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan E.","family":"Grund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxian","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo Jeon","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keilly","family":"Zelaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharan","family":"Bobbala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner","family":"Geldenhuys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariette","family":"Barbier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Rocco","family":"LaSala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Slawomir","family":"Lukomski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,30]]},"reference":[{"key":"225_CR1","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1128\/CMR.00101-13","volume":"27","author":"MJ Walker","year":"2014","unstructured":"Walker, M. J. et al. Disease manifestations and pathogenic mechanisms of group A Streptococcus. Clin. Microbiol. Rev. 27, 264\u2013301 (2014).","journal-title":"Clin. Microbiol. Rev."},{"key":"225_CR2","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/S1473-3099(05)70267-X","volume":"5","author":"JR Carapetis","year":"2005","unstructured":"Carapetis, J. R., Steer, A. C., Mulholland, E. K. & Weber, M. The global burden of group A streptococcal diseases. Lancet Infect. Dis. 5, 685\u2013694 (2005).","journal-title":"Lancet Infect. Dis."},{"key":"225_CR3","unstructured":"Prevention, C. F. D. C. A. 2019 antibiotic resistance threats report, https:\/\/www.cdc.gov\/antimicrobial-resistance\/data-research\/threats\/index.html (2019)."},{"key":"225_CR4","doi-asserted-by":"publisher","first-page":"e10","DOI":"10.1093\/cid\/ciu296","volume":"59","author":"DL Stevens","year":"2014","unstructured":"Stevens, D. L. et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 59, e10\u2013e52 (2014).","journal-title":"Clin. Infect. Dis."},{"key":"225_CR5","unstructured":"World Health Organization. Bacterial Priority Pathogens List 2024: bacterial pathogens of public health importance, to guide research, development, and strategies to prevent and control antimicrobial resistance (World Health Organization, 2024)."},{"key":"225_CR6","doi-asserted-by":"publisher","unstructured":"Berbel, D., Gonz\u00e1lez-D\u00edaz, A., L\u00f3pez de Egea, G., C\u00e0mara, J. & Ardanuy, C. An overview of macrolide resistance in streptococci: prevalence, mobile elements and dynamics. Microorganisms 10, https:\/\/doi.org\/10.3390\/microorganisms10122316 (2022).","DOI":"10.3390\/microorganisms10122316"},{"key":"225_CR7","unstructured":"Prevention, Cf. D. C. a. Erythromycin-resistant. group A Streptococcus. https:\/\/www.cdc.gov\/drugresistance\/pdf\/threats-report\/gas-508.pdf (2019)."},{"key":"225_CR8","unstructured":"Prevention, C. F. D. C. A. GAS surveillance report 2019, https:\/\/www.cdc.gov\/abcs\/downloads\/GAS_Surveillance_Report_2019.pdf (2020)."},{"key":"225_CR9","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1093\/cid\/ciab575","volume":"73","author":"K Fay","year":"2021","unstructured":"Fay, K. et al. Patterns of antibiotic nonsusceptibility among invasive group A Streptococcus infections-United States, 2006-2017. Clin. Infect. Dis. 73, 1957\u20131964 (2021).","journal-title":"Clin. Infect. Dis."},{"key":"225_CR10","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1586\/14787210.2015.1023292","volume":"13","author":"C Silva-Costa","year":"2015","unstructured":"Silva-Costa, C., Fri\u00e3es, A., Ramirez, M. & Melo-Cristino, J. Macrolide-resistant Streptococcus pyogenes: prevalence and treatment strategies. Expert Rev. Anti Infect. Ther. 13, 615\u2013628 (2015).","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"225_CR11","doi-asserted-by":"publisher","unstructured":"Villal\u00f3n, P. et al. National surveillance of tetracycline, erythromycin, and clindamycin resistance in invasive Streptococcus pyogenes: A retrospective study of the situation in Spain, 2007-2020. Antibiotics (Basel) 12 https:\/\/doi.org\/10.3390\/antibiotics12010099 (2023).","DOI":"10.3390\/antibiotics12010099"},{"key":"225_CR12","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.3389\/fmicb.2020.01547","volume":"11","author":"Y Li","year":"2020","unstructured":"Li, Y. et al. Genomic surveillance of Streptococcus pyogenes strains causing invasive disease, United States, 2016-2017. Front Microbiol 11, 1547 (2020).","journal-title":"Front Microbiol"},{"key":"225_CR13","doi-asserted-by":"publisher","first-page":"e3718","DOI":"10.1093\/cid\/ciaa787","volume":"73","author":"SJ Valenciano","year":"2021","unstructured":"Valenciano, S. J. et al. Invasive group A streptococcal infections among people who inject drugs and people experiencing homelessness in the United States, 2010-2017. Clin. Infect. Dis. 73, e3718\u2013e3726 (2021).","journal-title":"Clin. Infect. Dis."},{"key":"225_CR14","doi-asserted-by":"publisher","unstructured":"Gregory, C. J. et al. Invasive group A streptococcal infections in 10 U.S. states. JAMA, https:\/\/doi.org\/10.1001\/jama.2025.0910 (2025).","DOI":"10.1001\/jama.2025.0910"},{"key":"225_CR15","doi-asserted-by":"publisher","unstructured":"Powell, L. M. et al. Emergence of erythromycin-resistant invasive group A Streptococcus, West Virginia, USA, 2020-2021. Emerg. Infect. Dis. 29, https:\/\/doi.org\/10.3201\/eid2905.221421 (2023).","DOI":"10.3201\/eid2905.221421"},{"key":"225_CR16","doi-asserted-by":"publisher","unstructured":"Powell, L. M. et al. Prevalence of erythromycin-resistant emm92-type invasive group A streptococcal infections among injection drug users in West Virginia, United States, 2021-23. J. Antimicrob. Chemother. https:\/\/doi.org\/10.1093\/jac\/dkad268 (2023).","DOI":"10.1093\/jac\/dkad268"},{"key":"225_CR17","doi-asserted-by":"publisher","unstructured":"Sanson, M. A. et al. Unexpected relationships between frequency of antimicrobial resistance, disease phenotype and emm type in group A Streptococcus. Microb. Genom. 5, https:\/\/doi.org\/10.1099\/mgen.0.000316 (2019).","DOI":"10.1099\/mgen.0.000316"},{"key":"225_CR18","doi-asserted-by":"publisher","unstructured":"Li, Y. et al. Continued increase of erythromycin- and clindamycin-nonsusceptibility among invasive group A streptococci driven by genomic clusters, USA, 2018-2019. Clin. Infect. Dis. 76, https:\/\/doi.org\/10.1093\/cid\/ciac468 (2022).","DOI":"10.1093\/cid\/ciac468"},{"key":"225_CR19","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1093\/infdis\/jiac162","volume":"226","author":"B Metcalf","year":"2022","unstructured":"Metcalf, B. et al. Cluster transmission drives invasive group A Streptococcus disease within the United States and is focused on communities experiencing disadvantage. J. Infect. Dis. 226, 546\u2013553 (2022).","journal-title":"J. Infect. Dis."},{"key":"225_CR20","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.cell.2020.04.001","volume":"181","author":"JM Stokes","year":"2020","unstructured":"Stokes, J. M. et al. A deep learning approach to antibiotic discovery. Cell 181, 475\u2013483 (2020).","journal-title":"Cell"},{"key":"225_CR21","doi-asserted-by":"publisher","first-page":"e1010613","DOI":"10.1371\/journal.pcbi.1010613","volume":"18","author":"A Rahman","year":"2022","unstructured":"Rahman, A. et al. A machine learning model trained on a high-throughput antibacterial screen increases the hit rate of drug discovery. PLoS Comput. Biol. 18, e1010613 (2022).","journal-title":"PLoS Comput. Biol."},{"key":"225_CR22","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/nm.4306","volume":"23","author":"SM Corsello","year":"2017","unstructured":"Corsello, S. M. et al. The Drug Repurposing Hub: a next-generation drug library and information resource. Nat. Med. 23, 405\u2013408 (2017).","journal-title":"Nat. Med."},{"key":"225_CR23","unstructured":"Institute, B. Drug repurposing hub. https:\/\/repo-hub.broadinstitute.org\/repurposing#home."},{"key":"225_CR24","doi-asserted-by":"publisher","first-page":"3370","DOI":"10.1021\/acs.jcim.9b00237","volume":"59","author":"K Yang","year":"2019","unstructured":"Yang, K. et al. Analyzing learned molecular representations for property prediction. J. Chem. Inf. Model. 59, 3370\u20133388 (2019).","journal-title":"J. Chem. Inf. Model."},{"key":"225_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jac\/dkae380","volume":"80","author":"A Ishak","year":"2025","unstructured":"Ishak, A., Mazonakis, N., Spernovasilis, N., Akinosoglou, K. & Tsioutis, C. Bactericidal versus bacteriostatic antibacterials: clinical significance, differences and synergistic potential in clinical practice. J. Antimicrob. Chemother. 80, 1\u201317 (2025).","journal-title":"J. Antimicrob. Chemother."},{"key":"225_CR26","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.jaip.2024.09.010","volume":"13","author":"YW Jo","year":"2025","unstructured":"Jo, Y. W., Kwon, H. S., Min, J., Her, Y. & Kwon, J. W. Neuropsychiatric events related to montelukast and pranlukast in adults with asthma and rhinitis: a 10-year nationwide population-based study. J. Allergy Clin. Immunol. Pr. 13, 893\u2013902 (2025).","journal-title":"J. Allergy Clin. Immunol. Pr."},{"key":"225_CR27","doi-asserted-by":"publisher","first-page":"e21842","DOI":"10.1016\/j.heliyon.2023.e21842","volume":"9","author":"Y Mou","year":"2023","unstructured":"Mou, Y. et al. Meta-analysis of the relationship between montelukast use and neuropsychiatric events in patients with allergic airway disease. Heliyon 9, e21842 (2023).","journal-title":"Heliyon"},{"key":"225_CR28","doi-asserted-by":"publisher","first-page":"608930","DOI":"10.1155\/2014\/608930","volume":"2014","author":"AJ Theron","year":"2014","unstructured":"Theron, A. J. et al. Cysteinyl leukotriene receptor-1 antagonists as modulators of innate immune cell function. J. Immunol. Res. 2014, 608930 (2014).","journal-title":"J. Immunol. Res."},{"key":"225_CR29","unstructured":"Jin, W., Barzilay, D. R. & Jaakkola, T. in Proc. 37th International Conference on Machine Learning, Vol. 119 (eds Daum\u00e9 Hal, III & Singh Aarti) 4849\u2013\u20134859 (PMLR, Proceedings of Machine Learning Research, 2020)."},{"key":"225_CR30","doi-asserted-by":"publisher","unstructured":"Bessen, D. E., Smeesters, P. R. & Beall, B. W. Molecular epidemiology, ecology, and evolution of group A streptococci. Microbiol. Spectr. 6, https:\/\/doi.org\/10.1128\/microbiolspec.CPP3-0009-2018 (2018).","DOI":"10.1128\/microbiolspec.CPP3-0009-2018"},{"key":"225_CR31","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s44259-024-00062-3","volume":"2","author":"LM Powell","year":"2024","unstructured":"Powell, L. M. et al. Regulation of erm(T) MLSB phenotype expression in the emergent emm92 type group A Streptococcus. npj Antimicrob. Resist. 2, 44 (2024).","journal-title":"npj Antimicrob. Resist."},{"key":"225_CR32","doi-asserted-by":"publisher","unstructured":"Powell, L. M. et al. Transcriptome of macrolide-resistant emm92 invasive group A Streptococcus in response to erythromycin exposure. Microbiol. Resour. Announc. e0084025. https:\/\/doi.org\/10.1128\/mra.00840-25 (2025).","DOI":"10.1128\/mra.00840-25"},{"key":"225_CR33","doi-asserted-by":"publisher","first-page":"90","DOI":"10.3389\/fcimb.2016.00090","volume":"6","author":"BA Bachert","year":"2016","unstructured":"Bachert, B. A. et al. Unique footprint in the scl1.3 locus affects adhesion and biofilm formation of the invasive M3-type group A Streptococcus. Front. Cell Infect. Microbiol. 6, 90 (2016).","journal-title":"Front. Cell Infect. Microbiol."},{"key":"225_CR34","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1128\/IAI.67.4.1779-1788.1999","volume":"67","author":"S Lukomski","year":"1999","unstructured":"Lukomski, S. et al. Extracellular cysteine protease produced by Streptococcus pyogenes participates in the pathogenesis of invasive skin infection and dissemination in mice. Infect. Immun. 67, 1779\u20131788 (1999).","journal-title":"Infect. Immun."},{"key":"225_CR35","doi-asserted-by":"publisher","first-page":"6542","DOI":"10.1128\/IAI.68.12.6542-6553.2000","volume":"68","author":"S Lukomski","year":"2000","unstructured":"Lukomski, S. et al. Identification and characterization of the scl gene encoding a group A Streptococcus extracellular protein virulence factor with similarity to human collagen. Infect. Immun. 68, 6542\u20136553 (2000).","journal-title":"Infect. Immun."},{"key":"225_CR36","doi-asserted-by":"publisher","first-page":"e0008022","DOI":"10.1128\/iai.00080-22","volume":"90","author":"LA Vega","year":"2022","unstructured":"Vega, L. A. et al. The integrative conjugative element ICESpyM92 contributes to pathogenicity of emergent antimicrobial-resistant emm92 group A Streptococcus. Infect. Immun. 90, e0008022 (2022).","journal-title":"Infect. Immun."},{"key":"225_CR37","doi-asserted-by":"publisher","first-page":"7604","DOI":"10.1073\/pnas.112059299","volume":"99","author":"SB Joseph","year":"2002","unstructured":"Joseph, S. B. et al. Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc. Natl. Acad. Sci. USA 99, 7604\u20137609 (2002).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"225_CR38","doi-asserted-by":"crossref","unstructured":"Chochua, S. et al. Invasive group A streptococcal penicillin binding protein 2x variants associated with reduced susceptibility to \u03b2-lactam antibiotics in the United States, 2015-2021. Antimicrob. Agents Chemother. 66, e0080222 (2022).","DOI":"10.1128\/aac.00802-22"},{"key":"225_CR39","doi-asserted-by":"publisher","unstructured":"Musser, J. M. et al. Reduced in vitro susceptibility of Streptococcus pyogenes to \u03b2-lactam antibiotics associated with mutations in the pbp2x gene is geographically widespread. J. Clin. Microbiol. https:\/\/doi.org\/10.1128\/jcm.01993-19 (2020).","DOI":"10.1128\/jcm.01993-19"},{"key":"225_CR40","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/0002-9343(52)90293-3","volume":"13","author":"H Eagle","year":"1952","unstructured":"Eagle, H. Experimental approach to the problem of treatment failure with penicillin. Group A streptococcal infection in mice. Am. J. Med. 13, 389\u2013399 (1952).","journal-title":"Am. J. Med."},{"key":"225_CR41","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1093\/infdis\/158.1.23","volume":"158","author":"DL Stevens","year":"1988","unstructured":"Stevens, D. L., Gibbons, A. E., Bergstrom, R. & Winn, V. The Eagle effect revisited: efficacy of clindamycin, erythromycin, and penicillin in the treatment of streptococcal myositis. J. Infect. Dis. 158, 23\u201328 (1988).","journal-title":"J. Infect. Dis."},{"key":"225_CR42","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/S1473-3099(20)30523-5","volume":"21","author":"A Babiker","year":"2021","unstructured":"Babiker, A. et al. Effectiveness of adjunctive clindamycin in \u03b2-lactam antibiotic-treated patients with invasive \u03b2-haemolytic streptococcal infections in US hospitals: a retrospective multicentre cohort study. Lancet Infect. Dis. 21, 697\u2013710 (2021).","journal-title":"Lancet Infect. Dis."},{"key":"225_CR43","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1093\/cid\/ciac720","volume":"76","author":"N Cort\u00e9s-Penfield","year":"2023","unstructured":"Cort\u00e9s-Penfield, N. & Ryder, J. H. Should linezolid replace clindamycin as the adjunctive antimicrobial of choice in group A streptococcal necrotizing soft tissue infection and toxic shock syndrome? A focused Debate. Clin. Infect. Dis. 76, 346\u2013350 (2023).","journal-title":"Clin. Infect. Dis."},{"key":"225_CR44","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/nyas.14930","volume":"1519","author":"T Lluka","year":"2023","unstructured":"Lluka, T. & Stokes, J. M. Antibiotic discovery in the artificial intelligence era. Ann. N. Y. Acad. Sci. 1519, 74\u201393 (2023).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"225_CR45","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1021\/acs.accounts.0c00699","volume":"54","author":"WP Walters","year":"2021","unstructured":"Walters, W. P. & Barzilay, R. Applications of deep learning in molecule generation and molecular property prediction. Acc. Chem. Res 54, 263\u2013270 (2021).","journal-title":"Acc. Chem. Res"},{"key":"225_CR46","doi-asserted-by":"publisher","unstructured":"Caldara, M. & Marmiroli, N. Antimicrobial properties of antidepressants and antipsychotics-possibilities and implications. Pharmaceuticals 14, https:\/\/doi.org\/10.3390\/ph14090915 (2021).","DOI":"10.3390\/ph14090915"},{"key":"225_CR47","doi-asserted-by":"publisher","first-page":"e98","DOI":"10.1017\/ash.2025.73","volume":"5","author":"I Sears","year":"2025","unstructured":"Sears, I., Davis, M., Gibas, K., Mermel, L. & Heffernan, D. S. Antidepressants and antibiotic resistance in urine cultures: a cohort study. Antimicrob. Steward Health. Epidemiol. 5, e98 (2025).","journal-title":"Antimicrob. Steward Health. Epidemiol."},{"key":"225_CR48","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.1007\/s00705-016-2950-4","volume":"161","author":"XX Sheng","year":"2016","unstructured":"Sheng, X. X. et al. The LXR ligand GW3965 inhibits Newcastle disease virus infection by affecting cholesterol homeostasis. Arch. Virol. 161, 2491\u20132501 (2016).","journal-title":"Arch. Virol."},{"key":"225_CR49","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1021\/acschembio.0c00842","volume":"16","author":"M Shin","year":"2021","unstructured":"Shin, M. et al. Characterization of an antibacterial agent targeting ferrous iron transport protein FeoB against Staphylococcus aureus and gram-positive bacteria. ACS Chem. Biol. 16, 136\u2013149 (2021).","journal-title":"ACS Chem. Biol."},{"key":"225_CR50","doi-asserted-by":"publisher","first-page":"246","DOI":"10.12659\/MSMBR.889474","volume":"19","author":"S U\u00e7ar","year":"2013","unstructured":"U\u00e7ar, S. et al. Montelukast is as effective as penicillin in treatment of acute otitis media: an experimental rat study. Med. Sci. Monit. Basic Res. 19, 246\u2013252 (2013).","journal-title":"Med. Sci. Monit. Basic Res."},{"key":"225_CR51","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1177\/0300060518820412","volume":"47","author":"H Wu","year":"2019","unstructured":"Wu, H., Ding, X., Zhao, D., Liang, Y. & Ji, W. Effect of montelukast combined with methylprednisolone for the treatment of Mycoplasma pneumonia. J. Int. Med. Res. 47, 2555\u20132561 (2019).","journal-title":"J. Int. Med. Res."},{"key":"225_CR52","first-page":"4257","volume":"5","author":"MB Rahamati","year":"2017","unstructured":"Rahamati, M. B., Sabouri, S. & Sabouri, F. The efficacy of montelukast in adjunct with amoxicillin in treatment of Acute Otitis Media (AOM) in children. J Pediatr. Perspect. 5, 4257\u20134262 (2017).","journal-title":"J Pediatr. Perspect."},{"key":"225_CR53","doi-asserted-by":"crossref","unstructured":"El-Shehaby, N., El-Shahawy, H., Nasef, N., El-Sallab, S. & Elhalaby, H. Role of montelukast in modulation of response to sepsis in preterm infants: a randomized-controlled tria. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04474327 (2021).","DOI":"10.21203\/rs.3.rs-555613\/v1"},{"key":"225_CR54","unstructured":"ClinicalKey. Drug monograph montelukast. https:\/\/www.clinicalkey.com\/#!\/content\/drug_monograph\/6-s2.0-762."},{"key":"225_CR55","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1158\/2159-8290.CD-11-0102","volume":"1","author":"D Guo","year":"2011","unstructured":"Guo, D. et al. An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR\/AKT\/SREBP-1\/LDLR-dependent pathway. Cancer Discov. 1, 442\u2013456 (2011).","journal-title":"Cancer Discov."},{"key":"225_CR56","doi-asserted-by":"publisher","first-page":"5419","DOI":"10.1073\/pnas.0830671100","volume":"100","author":"BA Laffitte","year":"2003","unstructured":"Laffitte, B. A. et al. Activation of liver X receptor improves glucose tolerance through coordinate regulation of glucose metabolism in liver and adipose tissue. Proc. Natl. Acad. Sci. USA 100, 5419\u20135424 (2003).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"225_CR57","doi-asserted-by":"publisher","first-page":"647070","DOI":"10.3389\/fimmu.2021.647070","volume":"12","author":"P Wang","year":"2021","unstructured":"Wang, P. et al. Administration of GDF3 into septic mice improves survival via enhancing LXR\u03b1-mediated macrophage phagocytosis. Front. Immunol. 12, 647070 (2021).","journal-title":"Front. Immunol."},{"key":"225_CR58","doi-asserted-by":"crossref","unstructured":"Benne, N. et al. Complement receptor targeted liposomes encapsulating the liver X receptor agonist GW3965 accumulate in and stabilize atherosclerotic plaques. Adv. Health. Mater. 9, e2000043 (2020).","DOI":"10.1002\/adhm.202000043"},{"key":"225_CR59","doi-asserted-by":"publisher","first-page":"2831","DOI":"10.1101\/gad.850400","volume":"14","author":"JR Schultz","year":"2000","unstructured":"Schultz, J. R. et al. Role of LXRs in control of lipogenesis. Genes Dev. 14, 2831\u20132838 (2000).","journal-title":"Genes Dev."},{"key":"225_CR60","doi-asserted-by":"publisher","first-page":"11019","DOI":"10.1074\/jbc.M111041200","volume":"277","author":"SB Joseph","year":"2002","unstructured":"Joseph, S. B. et al. Direct and indirect mechanisms for regulation of fatty acid synthase gene expression by liver X receptors. J. Biol. Chem. 277, 11019\u201311025 (2002).","journal-title":"J. Biol. Chem."},{"key":"225_CR61","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1677\/JOE-09-0271","volume":"204","author":"C Zhao","year":"2010","unstructured":"Zhao, C. & Dahlman-Wright, K. Liver X receptor in cholesterol metabolism. J. Endocrinol. 204, 233\u2013240 (2010).","journal-title":"J. Endocrinol."},{"key":"225_CR62","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.cell.2004.09.032","volume":"119","author":"SB Joseph","year":"2004","unstructured":"Joseph, S. B. et al. LXR-dependent gene expression is important for macrophage survival and the innate immune response. Cell 119, 299\u2013309 (2004).","journal-title":"Cell"},{"key":"225_CR63","doi-asserted-by":"publisher","first-page":"2978","DOI":"10.1002\/1873-3468.12702","volume":"591","author":"IG Schulman","year":"2017","unstructured":"Schulman, I. G. Liver X receptors link lipid metabolism and inflammation. FEBS Lett. 591, 2978\u20132991 (2017).","journal-title":"FEBS Lett."},{"key":"225_CR64","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1161\/01.CIR.0000026802.79202.96","volume":"106","author":"GU Schuster","year":"2002","unstructured":"Schuster, G. U. et al. Accumulation of foam cells in liver X receptor-deficient mice. Circulation 106, 1147\u20131153 (2002).","journal-title":"Circulation"},{"key":"225_CR65","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.bcp.2005.11.004","volume":"71","author":"EG Lund","year":"2006","unstructured":"Lund, E. G. et al. Different roles of liver X receptor alpha and beta in lipid metabolism: effects of an alpha-selective and a dual agonist in mice deficient in each subtype. Biochem. Pharm. 71, 453\u2013463 (2006).","journal-title":"Biochem. Pharm."},{"key":"225_CR66","doi-asserted-by":"publisher","first-page":"419","DOI":"10.3389\/fphys.2018.00419","volume":"9","author":"P Krzyszczyk","year":"2018","unstructured":"Krzyszczyk, P., Schloss, R., Palmer, A. & Berthiaume, F. The role of macrophages in acute and chronic wound healing and interventions to promote pro-wound healing phenotypes. Front. Physiol. 9, 419 (2018).","journal-title":"Front. Physiol."},{"key":"225_CR67","doi-asserted-by":"publisher","first-page":"32197","DOI":"10.1074\/jbc.M605237200","volume":"281","author":"C Marathe","year":"2006","unstructured":"Marathe, C. et al. The arginase II gene is an anti-inflammatory target of liver X receptor in macrophages. J. Biol. Chem. 281, 32197\u201332206 (2006).","journal-title":"J. Biol. Chem."},{"key":"225_CR68","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1161\/CIRCRESAHA.111.241810","volume":"109","author":"B Pourcet","year":"2011","unstructured":"Pourcet, B. et al. LXR\u03b1 regulates macrophage arginase 1 through PU.1 and interferon regulatory factor 8. Circ. Res. 109, 492\u2013501 (2011).","journal-title":"Circ. Res."},{"key":"225_CR69","doi-asserted-by":"publisher","first-page":"115457","DOI":"10.1016\/j.intimp.2025.115457","volume":"166","author":"Q Jiang","year":"2025","unstructured":"Jiang, Q., Tang, Y. X. & Zhou, G. Cellular cholesterol metabolism rewiring through SREBP2-LXR-mTOR signaling convergence orchestrates T cell fate and keratinocyte apoptosis in oral lichen planus. Int. Immunopharmacol. 166, 115457 (2025).","journal-title":"Int. Immunopharmacol."},{"key":"225_CR70","doi-asserted-by":"publisher","first-page":"119434","DOI":"10.1016\/j.lfs.2021.119434","volume":"276","author":"W Zhang","year":"2021","unstructured":"Zhang, W. et al. Liver X receptor agonist GW3965 protects against sepsis by promoting myeloid derived suppressor cells apoptosis in mice. Life Sci. 276, 119434 (2021).","journal-title":"Life Sci."},{"key":"225_CR71","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1172\/JCI35288","volume":"119","author":"H Korf","year":"2009","unstructured":"Korf, H. et al. Liver X receptors contribute to the protective immune response against Mycobacterium tuberculosis in mice. J. Clin. Investig. 119, 1626\u20131637 (2009).","journal-title":"J. Clin. Investig."},{"key":"225_CR72","doi-asserted-by":"publisher","unstructured":"Happonen, L. & Collin, M. Immunomodulating enzymes from Streptococcus pyogenes-in pathogenesis, as biotechnological tools, and as biological drugs. Microorganisms 12, https:\/\/doi.org\/10.3390\/microorganisms12010200 (2024).","DOI":"10.3390\/microorganisms12010200"},{"key":"225_CR73","doi-asserted-by":"publisher","unstructured":"Rivera-Hernandez, T. et al. Vaccine-induced Th1-type response protects against invasive group A Streptococcus infection in the absence of opsonizing antibodies. mBio 11, https:\/\/doi.org\/10.1128\/mBio.00122-20 (2020).","DOI":"10.1128\/mBio.00122-20"},{"key":"225_CR74","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1002\/jps.10342","volume":"92","author":"M Xie","year":"2003","unstructured":"Xie, M. et al. Asparagine deamidation in recombinant human lymphotoxin: hindrance by three-dimensional structures. J. Pharm. Sci. 92, 869\u2013880 (2003).","journal-title":"J. Pharm. Sci."},{"key":"225_CR75","doi-asserted-by":"publisher","first-page":"dlaf021","DOI":"10.1093\/jacamr\/dlaf021","volume":"7","author":"LM Powell","year":"2025","unstructured":"Powell, L. M., Choi, S. J., LaSala, P. R. & Lukomski, S. Insights into MLS(B) resistance in invasive group A streptococci in West Virginia, USA. JAC Antimicrob. Resist 7, dlaf021 (2025).","journal-title":"JAC Antimicrob. Resist"},{"key":"225_CR76","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1111\/mmi.12125","volume":"87","author":"H Oliver-Kozup","year":"2013","unstructured":"Oliver-Kozup, H. et al. The group A streptococcal collagen-like protein-1, Scl1, mediates biofilm formation by targeting the extra domain A-containing variant of cellular fibronectin expressed in wounded tissue. Mol. Microbiol. 87, 672\u2013689 (2013).","journal-title":"Mol. Microbiol."},{"key":"225_CR77","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1118\/1.596340","volume":"16","author":"MD Powell","year":"1989","unstructured":"Powell, M. D. Multiphoton, time-of-flight three-dimensional radionuclide imaging. Med. Phys. 16, 809\u2013812 (1989).","journal-title":"Med. Phys."},{"key":"225_CR78","doi-asserted-by":"publisher","first-page":"2668","DOI":"10.1073\/pnas.88.7.2668","volume":"88","author":"JM Musser","year":"1991","unstructured":"Musser, J. M. et al. Streptococcus pyogenes causing toxic-shock-like syndrome and other invasive diseases: clonal diversity and pyrogenic exotoxin expression. Proc. Natl. Acad. Sci. USA 88, 2668\u20132672 (1991).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"225_CR79","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1086\/432514","volume":"192","author":"P Sumby","year":"2005","unstructured":"Sumby, P. et al. Evolutionary origin and emergence of a highly successful clone of serotype M1 group A Streptococcus involved multiple horizontal gene transfer events. J. Infect. Dis. 192, 771\u2013782 (2005).","journal-title":"J. Infect. Dis."},{"key":"225_CR80","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1002\/jps.2600580708","volume":"58","author":"HC Ansel","year":"1969","unstructured":"Ansel, H. C., Norred, W. P. & Roth, I. L. Antimicrobial activity of dimethyl sulfoxide against Escherichia coli, Pseudomonas aeruginosa, and Bacillus megaterium. J. Pharm. Sci. 58, 836\u2013839 (1969).","journal-title":"J. Pharm. Sci."},{"key":"225_CR81","unstructured":"Landrum, G. RDKit: a software suite for cheminformatics, computational chemistry, and predictive modeling. https:\/\/www.rdkit.org\/RDKit_Overview.pdf (2013)."},{"key":"225_CR82","unstructured":"Emery Pharma. Antimicrobial synergy study \u2013 checkerboard testing. http:\/\/emerypharma.com\/solutions\/cell-microbiology-services\/antimicrobial-synergy-study-checkerboard-testing\/ (2022)."},{"key":"225_CR83","doi-asserted-by":"publisher","first-page":"411","DOI":"10.3797\/scipharm.1002-07","volume":"78","author":"BR Challa","year":"2010","unstructured":"Challa, B. R., Awen, B. Z., Chandu, B. R., Khagga, M. & Kotthapalli, C. B. Method development and validation of montelukast in human plasma by HPLC coupled with ESI-MS\/MS: application to a bioequivalence study. Sci. Pharm. 78, 411\u2013422 (2010).","journal-title":"Sci. Pharm."}],"container-title":["npj Antimicrobials and Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s44259-026-00225-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44259-026-00225-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44259-026-00225-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:03:39Z","timestamp":1788221019000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s44259-026-00225-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,30]]},"references-count":83,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["225"],"URL":"https:\/\/doi.org\/10.1038\/s44259-026-00225-4","relation":{},"ISSN":["2731-8745"],"issn-type":[{"value":"2731-8745","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,30]]},"assertion":[{"value":"3 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"50"}}